Complejo Hospitalario Universitario De Ourense — Clinical Trial Site

69 Registered trials

27 Currently recruiting

Organisation

Complejo Hospitalario Universitario De Ourense

Location

Ourense, Spain

Identifier

ORG-100043872

Address

Calle De Ramon Puga Noguerol Nº 52, 32005, Spain

Departments

#760; Oncologia
1319: Hematología
7003; Oncology
7104: Hematologia
7108:Oncología
Allergology
Anestesiología y Reanimación
Digestive
Digestivo
Gastroenterology
Hematologia
Hematology
Hospital Santa Maria Nai, Servicio Oncologia
Medical Oncology
N/A
Oncología
Oncology
Oncology Department
Servicio de digestivo
Servicio de Hematologia
Servicio de Oncologia
Servicio de Oncología Médica

Clinical trials at this site (69)

Search interface

A trial comparing the treatment of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan to the standard treatment in patients with… Recruiting

2024-512583-57-00 HER2-positive locally advanced or metastatic gastric or 5 2025-07-30
A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit… Recruiting

2024-517247-31-00 Newly Diagnosed Higher Risk Myelodysplastic Syndrome 5 2025-07-07
A Worldwide Study Testing the New Drug Olverembatinib for Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2) Recruiting

2024-511495-32-00 Chronic Phase Chronic Myeloid Leukemia 5 2025-04-16
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
Study of treatment with sacituzumab and zimkberelimab for patients with lung cancer confined to the chest and previously operated on who wer… Recruiting

2024-512960-75-00 Resectable Non-small cell lung cancer 5 2025-02-04
A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch… Recruiting

2023-504899-25-00 Metastatic castration resistant prostate cancer 5 2024-04-04
A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting

2022-502113-28-00 Follicular lymphoma 5 2024-02-01
A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting

2024-514180-25-00 unresectable or metastatic HER2+ colorectal cancer 5 2022-11-21
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting

2023-508302-24-00 Locally Advanced/Metastatic Urothelial Cancer 4 2019-05-07
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Patients with invasive breast cancer in early stages 6 2018-01-10
A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Fluorouracil, … Ended

2024-513008-32-00 Adenocarcinoma of the gastroesophageal junction 4 2025-12-17
Master protocol of novel agents or combinations as perioperative treatment in participants with locally advanced resectable gastroesophagea… Ended

2024-516909-23-00 Locally Advanced Resectable Gastroesophageal Adenocarci 4 2025-10-28
A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C… Ended

2024-517422-25-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2025-05-22
A trial to learn how well AZD0901 works and how safe it is compared to standard cancer treatments in adults with advanced and metastatic gas… Ended

2023-508276-11-00 Gastric cancer, Advanced/Metastatic Gastric cancer, Gas 5 2025-01-17
A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot… Ended

2023-506668-15-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2024-06-17
A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-sm… Ended

2023-508359-38-00 Early-stage Non-squamous Non-small Cell Lung Cancer 5 2024-06-05
A Phase 3b Study of BMS-986346 in Lower-risk Myelodysplastic Syndrome Participants Ended

2023-504541-31-00 Myelodysplastic syndrome 5 2024-03-06
Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squam… Ended

2023-507448-36-00 Non-small Cell Lung Cancer 5 2024-02-16
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N… Ended

2022-500802-16-00 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non- 5 2023-11-01
A phase II prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG (Bacillus Calmette-Guérin… Ended

2024-518486-10-00 Non-Muscle Invasive Bladder Cancer 4 2023-02-23
Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended

2023-509429-37-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5 2022-10-03
Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended

2023-507933-12-00 Advanced or Metastatic Non-small Cell Lung Cancer (NSCL 5 2022-08-18
A Phase II clinical trial comparing the efficacy of RO7198457 versus watchful waiting in patients with ctDNA positive, resected Stage II (hi… Ended

2023-509516-28-00 Stage II/Stage III rectal cancer or Stage II (high risk 4 2021-02-22
This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Pat… Ended

2023-507338-26-00 Histologically documented gastric or gastroesophageal j 5 2021-02-01